Bristol Myers: new results for psoriasis
(CercleFinance.com) - Bristol Myers Squibb today announced new three-year results from the POETYK PSO long-term extension trial (LTE) of Sotyktu (deucravacitinib) in adult patients with moderate-to-severe plaque psoriasis.
It reports that long-term data for Sotyktu (deucravacitinib) demonstrate durable efficacy and consistent safety for up to three years in moderate-to-severe plaque psoriasis.
Sotyktu demonstrated a consistent safety profile with no increase in adverse events or serious adverse events, and no emergence of new safety signals
New data will be presented at the 2023 Congress of the European Academy of Dermatology and Venereology.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
It reports that long-term data for Sotyktu (deucravacitinib) demonstrate durable efficacy and consistent safety for up to three years in moderate-to-severe plaque psoriasis.
Sotyktu demonstrated a consistent safety profile with no increase in adverse events or serious adverse events, and no emergence of new safety signals
New data will be presented at the 2023 Congress of the European Academy of Dermatology and Venereology.
Copyright (c) 2023 CercleFinance.com. All rights reserved.